Gustavo A. Rosario Benitez

Array ( [id] => 16190800 [patent_doc_number] => 20200231649 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-23 [patent_title] => TCRS SPECIFIC FOR MINOR HISTOCOMPATIBILITY (H) ANTIGEN HA-1 AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/700998 [patent_app_country] => US [patent_app_date] => 2019-12-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26634 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16700998 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15586525 [patent_doc_number] => 20200069797 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-05 [patent_title] => COMBINATION THERAPIES AND METHODS USING ANTI-CD3 MODULATING AGENTS AND ANTI-IL-6 ANTAGONISTS [patent_app_type] => utility [patent_app_number] => 16/683584 [patent_app_country] => US [patent_app_date] => 2019-11-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16011 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16683584 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19955326 [patent_doc_number] => 12325733 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-06-10 [patent_title] => Binding domain [patent_app_type] => utility [patent_app_number] => 17/290188 [patent_app_country] => US [patent_app_date] => 2019-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 9 [patent_no_of_words] => 15549 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 731 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17290188 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19955326 [patent_doc_number] => 12325733 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-06-10 [patent_title] => Binding domain [patent_app_type] => utility [patent_app_number] => 17/290188 [patent_app_country] => US [patent_app_date] => 2019-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 9 [patent_no_of_words] => 15549 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 731 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17290188 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20466627 [patent_doc_number] => 12522660 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-01-13 [patent_title] => Methods for selection and stimulation of cells and apparatus for same [patent_app_type] => utility [patent_app_number] => 17/289690 [patent_app_country] => US [patent_app_date] => 2019-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 33 [patent_no_of_words] => 124981 [patent_no_of_claims] => 39 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 170 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17289690 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15931223 [patent_doc_number] => 20200157245 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-21 [patent_title] => METHODS FOR TREATING CONDITIONS ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION [patent_app_type] => utility [patent_app_number] => 16/591418 [patent_app_country] => US [patent_app_date] => 2019-10-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 87892 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16591418 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17292270 [patent_doc_number] => 20210388109 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-16 [patent_title] => COMPOSITIONS AND METHODS REGARDING ENGINEERED AND NON-ENGINEERED GAMMA DELTA T-CELLS FOR TREATMENT OF SOLID TUMORS [patent_app_type] => utility [patent_app_number] => 17/281886 [patent_app_country] => US [patent_app_date] => 2019-10-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15655 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -47 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17281886 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17292270 [patent_doc_number] => 20210388109 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-16 [patent_title] => COMPOSITIONS AND METHODS REGARDING ENGINEERED AND NON-ENGINEERED GAMMA DELTA T-CELLS FOR TREATMENT OF SOLID TUMORS [patent_app_type] => utility [patent_app_number] => 17/281886 [patent_app_country] => US [patent_app_date] => 2019-10-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15655 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -47 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17281886 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17292261 [patent_doc_number] => 20210388100 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-16 [patent_title] => COMPOSITIONS AND METHODS REGARDING ENGINEERED AND NON-ENGINEERED GAMMA DELTA T-CELLS FOR TREATMENT OF HEMATOLOGICAL TUMORS [patent_app_type] => utility [patent_app_number] => 17/281574 [patent_app_country] => US [patent_app_date] => 2019-10-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18538 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -47 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17281574 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15681311 [patent_doc_number] => 20200095319 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-26 [patent_title] => CROSS-SPECIES-SPECIFIC BISPECIFIC BINDERS [patent_app_type] => utility [patent_app_number] => 16/586318 [patent_app_country] => US [patent_app_date] => 2019-09-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 47458 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16586318 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17110145 [patent_doc_number] => 20210290742 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-23 [patent_title] => METHODS OF USING LYSINE DEACETYLASE (KDAC) INHIBITION TO GENERATE ANTIGEN SPECIFIC MEMORY T CELL RESPONSES FOR DURABLE IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 17/268806 [patent_app_country] => US [patent_app_date] => 2019-09-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7876 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17268806 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15800225 [patent_doc_number] => 20200123255 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-23 [patent_title] => HUMANIZED OR CHIMERIC CD3 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/582428 [patent_app_country] => US [patent_app_date] => 2019-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43032 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16582428 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15800225 [patent_doc_number] => 20200123255 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-23 [patent_title] => HUMANIZED OR CHIMERIC CD3 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/582428 [patent_app_country] => US [patent_app_date] => 2019-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43032 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16582428 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19897867 [patent_doc_number] => 12275773 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-04-15 [patent_title] => High affinity cell receptor for recognizing AFP antigen [patent_app_type] => utility [patent_app_number] => 17/278504 [patent_app_country] => US [patent_app_date] => 2019-09-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 116 [patent_no_of_words] => 17866 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 142 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17278504 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18762996 [patent_doc_number] => 11813376 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-11-14 [patent_title] => Cellular compositions derived from deceased donors to promote graft tolerance and manufacture and uses thereof [patent_app_type] => utility [patent_app_number] => 16/574867 [patent_app_country] => US [patent_app_date] => 2019-09-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 18873 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16574867 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15621203 [patent_doc_number] => 20200081006 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-12 [patent_title] => Method for Treating Rheumatoid Arthritis [patent_app_type] => utility [patent_app_number] => 16/572432 [patent_app_country] => US [patent_app_date] => 2019-09-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5807 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16572432 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16072457 [patent_doc_number] => 20200190215 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-18 [patent_title] => Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation [patent_app_type] => utility [patent_app_number] => 16/570185 [patent_app_country] => US [patent_app_date] => 2019-09-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 66980 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16570185 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17412806 [patent_doc_number] => 20220047710 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-17 [patent_title] => SINGLE CHAIN CONSTRUCTS [patent_app_type] => utility [patent_app_number] => 17/275808 [patent_app_country] => US [patent_app_date] => 2019-09-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20311 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -124 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17275808 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18504654 [patent_doc_number] => 11702459 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-07-18 [patent_title] => MR1 restricted T cell receptors for cancer immunotherapy [patent_app_type] => utility [patent_app_number] => 16/563987 [patent_app_country] => US [patent_app_date] => 2019-09-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 13758 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 81 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16563987 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16671301 [patent_doc_number] => 20210060064 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-04 [patent_title] => METHODS OF TREATING AGING-RELATED DISORDERS [patent_app_type] => utility [patent_app_number] => 16/557875 [patent_app_country] => US [patent_app_date] => 2019-08-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 203982 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16557875 [rel_patent_id] =>[rel_patent_doc_number] =>)